The Gut–Brain Axis Is a Network, Not a Line

The gut–brain axis is best understood as an interacting network rather than a direct line from intestinal bacteria to a particular thought, mood or symptom. Neural sensing, endocrine responses, microbial metabolism and immune activity offer different routes of communication. Their biological reality does not make them interchangeable explanations for an individual presentation. [1] [2]

That distinction is the starting point for this series from Living Well Today. The interesting question is no longer simply whether the gut and brain communicate. It is which signal is involved, where it originates, how it reaches a responsive tissue, and what kind of evidence connects that sequence to a clinically meaningful outcome.

For practitioners and highly engaged readers, this demands more than learning a list of pathways. It requires keeping anatomy, timescale, experimental context and clinical inference separate long enough to understand how they fit together.

Start with the system, not the microbiome

The gut–brain axis and the microbiota–gut–brain axis are related terms, but they are not exact synonyms. Digestive function is coordinated through local enteric circuits, communication with the central nervous system and hormonal signaling. The enteric nervous system contributes to movement and secretion within the digestive tract. Microorganisms participate in this wider system; they do not replace its neural and endocrine organization. [1]

This matters because a microbial explanation can become the default before other explanations have been considered. A person with abdominal discomfort and disrupted concentration may indeed have a relevant gut–brain interaction. That observation alone does not identify a microbial disturbance, establish the direction of influence or explain which component should be targeted.

A useful working model is therefore a network of interacting compartments: the intestinal lumen, epithelial surface, enteric nervous system, immune environment, circulation and central nervous system. This is an organizing model, not a claim that every compartment has been shown to be abnormal in every symptomatic person.

The model becomes useful when it helps generate narrower questions. It becomes less useful when the phrase “everything is connected” is allowed to substitute for an explanation.

Neural communication can be fast and anatomically specific

One important advance came from Kaelberer and colleagues in 2018. In mouse experiments, the investigators identified enteroendocrine cells that formed synaptic connections with vagal neurons and transmitted luminal nutrient information through glutamatergic signaling. These “neuropod” cells provided a rapid neuroepithelial route between the intestinal lumen and brainstem, rather than relying only on slower hormonal diffusion. [3]

The significance is anatomical as much as conceptual. A defined sensor, transmitter and neural connection create a testable circuit. That is a stronger statement than saying that the gut “sends messages” to the brain.

It is also a narrower statement than the popular interpretation. Demonstrating rapid nutrient sensing does not establish that a particular microbiome pattern causes depression, that every digestive complaint reflects impaired vagal function, or that stimulating a nerve will reproduce the effect of changing the luminal signal.

These are different hypotheses. Each would require its own evidence.

In reading mechanistic work, it helps to identify whether researchers manipulated the input, the sensor, the transmitter, the neural relay or the endpoint. A study that changes one step may reveal an important causal role without explaining the entire clinical problem.

The direction of influence runs both ways

The brain-to-gut side deserves as much attention as the gut-to-brain side. Schneider and colleagues’ 2023 work connected chronic stress signaling with changes in enteric glia and neurons in experimental models. The reported pathways included glucocorticoid-driven glial signaling associated with monocyte-mediated inflammation, as well as altered neuronal maturation and motility. Human inflammatory bowel disease cohorts supplied complementary associations, not a complete experimental replication of the mouse mechanism. [4]

This is a useful example of how a mechanistic paper can deepen an established clinical observation without simplifying it. The work does not mean inflammatory bowel disease is “caused by stress,” nor that controlling stress replaces disease-specific treatment. It illustrates that central stress responses can modify peripheral biology through identifiable intermediates.

When two symptom domains change together, either may influence the other, both may reflect a third factor, or several feedback processes may operate simultaneously. A network framework keeps those possibilities open. A one-way narrative tends to close them prematurely.

The language used with patients matters here. Recognizing a role for psychological stress should increase the sophistication of the physiological explanation, not diminish the legitimacy of the person’s symptoms.

Endocrine responses add a different timescale

The hypothalamic–pituitary–adrenal axis is another route through which microbial and host physiology have been investigated. In a foundational 2004 study, Sudo and colleagues found altered stress-hormone responses in germ-free mice. The timing of microbial colonization influenced whether those responses could be modified, drawing attention to developmental windows rather than only the adult microbial state. [5]

The developmental context is essential. Germ-free animals are not ordinary animals that happen to have a somewhat different stool profile. They have developed without the usual microbial exposures. An effect in that model may reveal what microbial signals contribute to development, but it cannot automatically predict what changing the adult human microbiome will accomplish.

This distinction also applies to timing. A rapid neural response, an endocrine response over minutes or hours, and developmental programming over a much longer period are not the same phenomenon. Combining them under one heading is useful for orientation; treating them as a single therapeutic target is not.

A careful reading therefore asks not only “what changed?” but “when was the system altered, and was the change reversible under the conditions studied?”

Microbial metabolites are signals with destinations

Microorganisms can influence host physiology through chemical products. Yet a microbial capacity to synthesize a substance is only one stage in a longer causal chain. Production, availability, absorption, host metabolism, tissue exposure and receptor response all matter.

Yano and colleagues demonstrated that selected gut bacteria and associated metabolites influenced serotonin production by host enterochromaffin cells in experimental systems. The physiological findings concerned intestinal and peripheral serotonin, including effects on motility and platelet function. They did not show that a stool result measures serotonin availability in the brain. [6]

That last distinction is frequently lost. The same chemical name appearing in gastrointestinal and neuroscience literature does not make measurements from those compartments equivalent. A claim about local biosynthesis should not silently become a claim about central neurotransmission.

Tryptophan metabolism provides another example of specificity. Rothhammer and colleagues investigated microbial metabolites, aryl hydrocarbon receptor signaling and astrocyte responses in experimental central nervous system inflammation, with human tissue findings contributing context. The work supports investigation of a defined signaling route; it does not establish a general treatment for people with nonspecific cognitive symptoms. [7]

The stronger question is not “does this substance affect the brain?” It is “which metabolite, at what exposure, through which receptor, in which tissue and under what conditions?” That wording makes the hypothesis harder to market but easier to test.

Immune communication is not a synonym for damage

The studies discussed here show why immune signaling belongs in a gut–brain model. Enteric glia, inflammatory mediators and central glial responses can participate in communication between tissues. They also show why the word “inflammation” needs an object: which cells, which mediators, which compartment and which measured endpoint? [4] [7]

A diagram containing an inflammatory arrow does not establish chronic neuroinflammation in the person sitting across the desk. Neither does a symptom such as fatigue provide a direct measurement of immune activity in the brain.

This is not a reason to avoid neuroimmune hypotheses. It is a reason to state them at the correct level. A hypothesis might concern a documented inflammatory disease, an experimental pathway, an observed biomarker association or an unexplained symptom pattern. Those are distinct starting points.

Part 2 of this series examines the intestinal and blood–brain barriers more closely, including why evidence of altered permeability at one interface cannot simply be transferred to another.

Human associations are valuable—and still associations

Valles-Colomer and colleagues’ 2019 population study linked features of the gut microbiome with quality of life and depression measures, with validation in additional datasets. The study also considered microbial neuroactive potential and important confounders. This made it a substantial contribution to human research in a field heavily shaped by animal experiments. [8]

Its value does not depend on pretending it proved a treatment. An association between a microbial feature and depression can support further investigation while leaving directionality, residual confounding and individual prediction unresolved.

Consider the difference between three questions: whether a feature differs on average between groups; whether it predicts outcomes in a new population; and whether changing it improves those outcomes. Success at the first does not guarantee success at the second or third.

Medication exposure, diet, illness and behavior can complicate interpretation. The same features that make human research clinically relevant also make causal inference difficult. The 2025 microbiome causality consensus emphasizes the need to connect experimental models, mechanistic evidence and human investigation rather than allowing any one layer to stand for all the others. [2]

A practical way to read the next gut–brain paper

Before adopting a conclusion, identify the actual unit of evidence. Was this a cell experiment, an animal intervention, a human observational study or a randomized clinical trial? Then identify the endpoint. A gene-expression change, a permeability measurement, a symptom score and a reduction in disability answer different questions.

Next ask whether the proposed mediator was measured directly. A change in microbial composition does not, by itself, show that a particular metabolite changed. A metabolite change does not prove that the target tissue received a biologically relevant exposure. An improved symptom score does not identify which proposed pathway mediated that improvement.

Finally, distinguish the research measurement from a clinical service. An international consensus on microbiome testing described major gaps in clinical utility and cautioned against inappropriate commercial testing. A technology’s ability to produce detailed information is not equivalent to evidence that the information improves clinical decisions. [9]

These questions are an interpretive framework, not a demand that every useful study solve every problem. Foundational studies are allowed to be foundational. The mistake is assigning them conclusions they were not designed to support.

What a network perspective changes

A serious gut–brain framework does not require abandoning diagnostic categories or treating the entire body as one undifferentiated problem. It asks for better specification: the relevant phenotype, plausible pathways, competing explanations and evidence needed to choose between them.

It also changes the standard for a persuasive explanation. Biological plausibility is a beginning. Clinical relevance requires more. The most compelling story is not necessarily the one with the largest number of arrows; it is the one that remains coherent when alternative explanations and contrary findings are taken seriously.

At Living Well Today, this series is intended to create room for that deeper conversation. The objective is not to reduce complexity to a slogan, but to make complexity more interpretable.

Continue with Part 2, “Barrier Biology: The Intestinal Barrier, Blood–Brain Barrier, and Neuroimmune Signaling.”

Educational discussion for practitioners and engaged readers. This article does not establish a diagnosis or provide an individualized treatment plan.

References

[1] National Institute of Diabetes and Digestive and Kidney Diseases. Your Digestive System & How It Works.Read source ↗

[2] Metwaly A, et al. A Consensus Statement on establishing causality, therapeutic applications and the use of preclinical models in microbiome research. Nature Reviews Gastroenterology & Hepatology. 2025;22:343-356.Read source ↗

[3] Kaelberer MM, et al. A gut-brain neural circuit for nutrient sensory transduction. Science. 2018;361:eaat5236.Read source ↗

[4] Schneider KM, et al. The enteric nervous system relays psychological stress to intestinal inflammation. Cell. 2023;186:2823-2838.e20.Read source ↗

[5] Sudo N, et al. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. Journal of Physiology. 2004;558:263-275.Read source ↗

[6] Yano JM, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015;161:264-276.Read source ↗

[7] Rothhammer V, et al. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nature Medicine. 2016;22:586-597.Read source ↗

[8] Valles-Colomer M, et al. The neuroactive potential of the human gut microbiota in quality of life and depression. Nature Microbiology. 2019;4:623-632.Read source ↗

[9] Porcari S, et al. International consensus statement on microbiome testing in clinical practice. Lancet Gastroenterology & Hepatology. 2025;10:154-167.Read source ↗